Circumvent the Tariff challenges with an agile supply chain Consulting
Supply Chain Ecosystem Analysis now part of DBMR Reports
Global Asthma Disease Market
Market Size in USD Billion
CAGR :
%
USD
24,847.56 Million
USD
34,798.31 Million
2022
2030
Forecast Period
2023 –2030
Market Size(Base Year)
USD
24,847.56 Million
Market Size (Forecast Year)
USD
34,798.31 Million
CAGR
4.30
%
Major Markets Players
Merck &
Co.Inc.
Sanofi
Novartis AG
Astellas Pharma Inc.
Global Asthma Disease Market, By Classification Type (Mild Intermittent Asthma, Mild Persistent Asthma, Moderate Persistent Asthma and Severe Persistent Asthma), Duration of Action Type (Long-Term Asthma Control Medications, Inhaled Corticosteroids, Anticholinergics, Tiotropium Bromide, Leukotriene Modifiers, Long-Acting Beta Agonists, Salmeterol, Formoterol, Arformoterol, Theophylline, Quick-relief (rescue) Medications, Short Acting Beta Agonists, Albuterol sulphate, Salbutamol, Allergy Medications, Allergy Shots (immunotherapy), Omalizumab (Xolair) and Others), Route of Administration (Oral, Inhaled, Intravenous and Others), End-Users (Hospitals, Homecare, Specialty Clinics and Others) – Industry Trends and Forecast to 2030.
Asthma Disease Market Analysis and Size
According to the global asthma report, an estimated 339 million people worldwide have asthma. It is one of the most common chronic diseases globally. The incidence of asthma can be influenced by factors such as genetics, environmental exposures (such as allergens and pollutants), socio-economic status, and healthcare access. However, the burden of asthma in low- and middle-income countries is increasing due to various factors such as urbanization, changing lifestyles, and exposure to environmental triggers.
Data Bridge Market Research analyses that the asthma disease market which was USD 24,847.56 million in 2022, would rocket up to USD 34,798.31 million by 2030, and is expected to undergo a CAGR of 4.3% during the forecast period. This indicates the market value. “Quick-relief (rescue) Medications” dominates the duration of action type segment of the asthma disease market owing to the growing demand for better methods for treatment in asthma patients. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Asthma Disease Market Scope and Segmentation
Report Metric
Details
Forecast Period
2023 to 2030
Base Year
2022
Historic Years
2021 (Customizable to 2015-2020)
Quantitative Units
Revenue in USD Million, Volumes in Units, and Pricing in USD
Segments Covered
Classification Type (Mild Intermittent Asthma, Mild Persistent Asthma, Moderate Persistent Asthma and Severe Persistent Asthma), Duration of Action Type (Long-Term Asthma Control Medications, Inhaled Corticosteroids, Anticholinergics, Tiotropium Bromide, Leukotriene Modifiers, Long-Acting Beta Agonists, Salmeterol, Formoterol, Arformoterol, Theophylline, Quick-relief (rescue) Medications, Short Acting Beta Agonists, Albuterol sulphate, Salbutamol, Allergy Medications, Allergy Shots (immunotherapy), Omalizumab (Xolair) and Others), Route of Administration (Oral, Inhaled, Intravenous and Others), End-Users (Hospitals, Homecare, Specialty Clinics and Others)
Countries Covered
U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, Rest of Middle East and Africa
Market Players Covered
Merck & Co., Inc. (U.S.), Sanofi (France), Novartis AG (Switzerland), Astellas Pharma Inc. (Japan), Pfizer Inc. (U.S.), Abbott (U.S.), Eli Lilly and Company (U.S.), Bristol-Myers Squibb Company (U.S.), Takeda Pharmaceutical Company Limited. (Japan), F. Hoffmann-La Roche Ltd (Switzerland), Boehringer Ingelheim International GmbH (Germany), Mylan N.V (U.S.), GlaxoSmithKline plc (U.K.), Regeneron Pharmaceuticals Inc (U.S.), AstraZeneca (U.K.), AbbVie Inc. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Vectura Group plc (U.K.), Sunovion Pharmaceuticals Inc. (U.S.) and Alkermes (Ireland), among others
Market Opportunities
Rising focus on pediatric asthma
Technological advancements in inhaler devices
Market Definition
Asthma is a respiratory disease that results in narrowing the airways which leads to difficulty in breathing. Asthma leads to excessive development of mucous in the windpipe which results in period but repetitive attack of breathlessness. Asthma also brings along chest pain, coughing and congestion. Asthma results in lung inflammation and tightens the muscles.
Global Asthma Disease Market Dynamics
Drivers
Increasing Prevalence of Asthma Disease
The rising prevalence of asthma worldwide is a significant driver of the asthma disease market. Factors such as environmental pollution, urbanization, and changes in lifestyle contribute to the increasing incidence of asthma
Growing Awareness and Diagnosis
Increasing awareness about asthma and its symptoms has led to improved diagnosis rates. This in turn, drives the demand for asthma treatments and medications
Government Initiatives and Healthcare Policies
Government initiatives focused on improving asthma management, providing better access to healthcare, and raising awareness about asthma contribute to the growth of the market. Healthcare policies that support affordable and accessible asthma treatments also drive market expansion
Increasing Healthcare Expenditure
The rise in healthcare expenditure, particularly in developing countries, supports the growth of the asthma disease market. Increased spending on healthcare infrastructure, research and development, and access to medications positively impacts market growth
Opportunities
Rising Focus on Pediatric Asthma
Pediatric asthma is a significant market opportunity, as the prevalence of asthma in children continues to rise. There is a need for age-appropriate asthma medications, devices, and management strategies to address the unique challenges faced by children with asthma
Technological Advancements in Inhaler Devices
Inhaler devices play a crucial role in asthma management. Advancements in inhaler technology, such as smart inhalers and digital health solutions, present opportunities for improved medication adherence, monitoring, and patient engagement
Restraints/Challenges
High Cost of Treatment
The cost of asthma medications, particularly newer biologics and targeted therapies, can be high. This can limit access to these treatments, especially in developing countries or for individuals without adequate insurance coverage. Affordability remains a significant challenge in the asthma disease market
Lack of Awareness and Under Diagnosis
Despite efforts to raise awareness about asthma, there is still a significant proportion of undiagnosed or underdiagnosed cases. Lack of awareness among patients and healthcare providers can lead to delayed diagnosis and inadequate management of asthma
Limited Treatment Options for Severe Asthma
While advancements have been made in the treatment of asthma, there is still a need for more effective and targeted therapies, especially for individuals with severe asthma. Limited treatment options for severe asthma pose a challenge in achieving optimal asthma control for these patients
Regulatory and Reimbursement Challenges
Regulatory requirements and reimbursement policies can pose challenges for market players. Obtaining regulatory approvals and reimbursement coverage for asthma medications and devices can be time-consuming and costly, impacting market entry and adoption
This asthma disease market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the asthma disease market contact Data Bridge Market Research for an analyst brief, our team will help you make an informed market decision to achieve market growth
Recent Developments
In May 2021, AstraZeneca announced positive results from their Phase III ETHOS trial evaluating their biologic therapy, tezepelumab, in patients with severe, uncontrolled asthma. The trial showed that tezepelumab significantly reduced asthma exacerbations and improved lung function compared to standard of care
In April 2021, GSK announced that their biologic therapy, mepolizumab, received FDA approval for use in children aged 6 to 11 with severe eosinophilic asthma. This expanded the indication for mepolizumab, which was previously approved for use in patients aged 12 and older
Global Asthma Disease Market Scope
The asthma disease market is segmented on the basis of classification type, duration of action type, route of administration and end-users. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Classification Type
Mild Intermittent Asthma
Mild Persistent Asthma
Moderate Persistent Asthma
Severe Persistent Asthma
Duration of Action Type
Long-Term Asthma Control Medications
Inhaled Corticosteroids
Beclomethasone Dipropionate
Omalizumab
Fluticasone Furoate Inhalation Powder
Prednisone Delayed-Release Tablets
Mometasone Furoate
Formoterol Fumarate Dehydrate
Anticholinergics
Tiotropium Bromide
Leukotriene Modifiers
Reslizumab
Mepolizumab
Montelukast.
Long-Acting Beta Agonists
Salmeterol
Formoterol
Arformoterol
Theophylline
Quick-relief (rescue) Medications
Short Acting Beta Agonists
Albuterol sulphate
Salbutamol
Allergy Medications
Allergy Shots (Immunotherapy)
Omalizumab (Xolair)
Others
Route of Administration
Oral
Inhaled
Intravenous
Others
End-Users
Hospitals
Homecare
Specialty Clinics
Others
Global Asthma Disease Market Regional Analysis/Insights
The global asthma disease market is analysed and market size insights and trends are provided by classification type, duration of action type, route of administration and end users as referenced above.
The countries covered in the asthma disease market report are U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, Rest of Middle East and Africa.
North America dominates the asthma disease market because of the strong base of healthcare facilities, the strong presence of major players in the market, the extraordinary healthcare infrastructure, and the large pool of people having respiratory diseases specifically asthma.
Asia-Pacific is expected to witness significant growth during the forecast period of 2023 to 2030 due to the increase in government initiatives to promote healthcare, the rising health awareness among the people and growing demand for advanced medical technology for diagnosis and treatment procedures, the large population pool, and the growing demand for quality healthcare in the region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as down-stream and up-stream value chain analysis, technical trends, and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs, and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Asthma Disease Market Share Analysis
The asthma disease market competitive landscape provides details by competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width, and breadth, application dominance. The above data points provided are only related to the company’s focus related to the asthma disease market.
Some of the major players operating in the asthma disease market are:
Merck & Co., Inc. (U.S.)
Sanofi (France)
Novartis AG (Switzerland)
Astellas Pharma Inc. (Japan)
Pfizer Inc. (U.S.)
Abbott (U.S.)
Eli Lilly and Company (U.S.)
Bristol-Myers Squibb Company (U.S.)
Takeda Pharmaceutical Company Limited. (Japan)
F. Hoffmann-La Roche Ltd (Switzerland)
Boehringer Ingelheim International GmbH (Germany)
Mylan N.V (U.S.)
GlaxoSmithKline plc (U.K.)
Regeneron Pharmaceuticals Inc (U.S.)
AstraZeneca (U.K.)
AbbVie Inc. (U.S.)
Teva Pharmaceutical Industries Ltd. (Israel)
Vectura Group plc (U.K.)
Sunovion Pharmaceuticals Inc. (U.S.)
Alkermes (Ireland)
SKU-37136
Get online access to the report on the World's First Market Intelligence Cloud
Interactive Data Analysis Dashboard
Company Analysis Dashboard for high growth potential opportunities
Research Analyst Access for customization & queries
Competitor Analysis with Interactive dashboard
Latest News, Updates & Trend analysis
Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Research Methodology
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Customization Available
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
Claudio Rondena
Group Business Development & Strategic Marketing Director, C.O.C Farmaceutici SRL
"This morning we were involved in the first part, the data presentation of MKT analysis, selected abstract from your work. The board team was really impressed and very appreciated, as well."
David Manning - Thermo Fisher Scientific
Director, Global Strategic Accounts,
Dear Ricky, I want to thank you for the excellent market analysis (LIMS INSTALLED BASE DATA) that you and your team delivered, especially end of year on short notice.
Sachin and Shraddha captured the requirements, determined their path forward and executed quickly.
You, Sachin and Shraddha have been a pleasure to work with – very responsive, professional and thorough.
Your work is much appreciated.
Manager - Market Analytics,
Uriah D. Avila - Zeus Polymer Solutions
Thank you for all the assistance and the level of detail in the market report. We are very pleased with the results and the customization. We would like to continue to do business.
Business Development Manager,
(Pharmaceuticals Partner for Nasal Sprays) | Renaissance Lakewood LLC
DBMR was attentive and engaged while discussing the Global Nasal Spray Market. They understood what we were looking for and was able to provide some examples from the report as requested. DBMR Service team has been responsive as needed. Depending on what my colleagues were looking for, I will recommend your services and would be happy to stay connected in case we can utilize your research in the future.
Business Intelligence and Analytics,
Ipsen Biopharm Limited
We are impressed by the CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT report - so a BIG thanks to you colleagues.
Competition Analyst,
Basler Web
I just wanted to share a quick note and let you know that you guys did a really good job. I’m glad I decided to work with you. I shall continue being associated with your company as long as we have market intelligence needs.
Marketing Director,
Buhler Group
It was indeed a good experience, would definitely recommend and come back for future prospects.
COO,
A global leader providing Drug Delivery Services
DBMR did an outstanding job on the Global Drug Delivery project, We were extremely impressed by the simple but comprehensive presentation of the study and the quality of work done. This report really helped us to access untapped opportunities across the globe.
Marketing Director,
Philips Healthcare
The study was customized to our targets and needs with well-defined milestones. We were impressed by the in-depth customization and inclusion of not only major but also minor players across the globe. The DBMR Market position grid helped us to analyze the market in different dimension which was very helpful for the team to get into the minute details.
Product manager,
Fujifilms
Thankful to the team for the amazing coordination, and helping me at the last moment with my presentation. It was indeed a comprehensive report that gave us revenue impacting solution enabling us to plan the right move.
Investor relations,
GE Healthcare
Thank you for the report, and addressing our needs in such short time. DBMR has outdone themselves in this project with such short timeframe.
Market Analyst,
Medincell
We found the results of this study compelling and will help our organization validate a market we are considering to enter. Thank you for a job well done.
Andrew - Senior Global Marketing Manager,
Medtronic (US)
I want to thank you for your help with this report – It’s been very helpful in our business planning and it well organized.
Amarildo - Manager, Global Strategic Alignment
MasterCard
We believe the work done by Data Bridge Team for our requirements in the North America Loyalty Management Market was fantastic and would love to continue working with your team moving forward.
Tor Hammer
Green Nexus LLc
Thank you for your quick response to this unfortunate circumstance. Please extend my thanks to your reach team. I will be contacting you in the future with further projects
I acknowledge the difficulty given by the very short warning for this report, and I think that its quality and your delivering time have been very satisfying.
Obviously, as a provider Data Bridge Market Research will be considered as a plus for future needs of Nippon Gases.
Yuki Kopyl (Asian Business Development Department)
UENO FOOD TECHNO INDUSTRY, LTD. (JAPAN)
Xylose report was very useful for our team. Thank you very much & hope to work with you again in the future